Clinical Trial

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.
Protocol Amendment History 4 changes
notable Trial sites expanded: 53 -> 56 locations 2026-07-28
notable Trial sites expanded: 46 -> 51 locations 2026-06-02
notable Trial sites expanded: 32 -> 46 locations 2026-05-05
notable Trial sites expanded: 23 -> 32 locations 2026-04-04
Trial Details
NCT Number NCT07137598
Lead Sponsor Hoffmann-La Roche
Conditions Rheumatoid Arthritis
Enrollment 160 participants
Start Date 2025-12-05
Primary Completion 2027-04-19 (estimated)
Study Completion 2027-10-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-27